Role of Seipin in Human Diseases and Experimental Animal Models
2022
Yuying Li | Xinmin Yang | Linrui Peng | Qing Xia | Yuwei Zhang | Wei Huang | Tingting Liu | Da Jia
Seipin, a protein encoded by the Berardinelli-Seip congenital lipodystrophy type 2 (<i>BSCL2</i>) gene, is famous for its key role in the biogenesis of lipid droplets and type 2 congenital generalised lipodystrophy (CGL2). <i>BSCL2</i> gene mutations result in genetic diseases including CGL2, progressive encephalopathy with or without lipodystrophy (also called Celia’s encephalopathy), and <i>BSCL2</i>-associated motor neuron diseases. Abnormal expression of seipin has also been found in hepatic steatosis, neurodegenerative diseases, glioblastoma stroke, cardiac hypertrophy, and other diseases. In the current study, we comprehensively summarise phenotypes, underlying mechanisms, and treatment of human diseases caused by <i>BSCL2</i> gene mutations, paralleled by animal studies including systemic or specific <i>Bscl2</i> gene knockout, or <i>Bscl2</i> gene overexpression. In various animal models representing diseases that are not related to <i>Bscl2</i> mutations, differential expression patterns and functional roles of seipin are also described. Furthermore, we highlight the potential therapeutic approaches by targeting seipin or its upstream and downstream signalling pathways. Taken together, restoring adipose tissue function and targeting seipin-related pathways are effective strategies for CGL2 treatment. Meanwhile, seipin-related pathways are also considered to have potential therapeutic value in diseases that are not caused by <i>BSCL2</i> gene mutations.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals